Into a Deeper Understanding of CYP2D6’s Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126350 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Mariana Bondrescu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2D6, Risperidone, Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babes” University of Medicine and Pharmacy Timisoara.
Abstract (Originalsprache)
Schizophrenia spectrum disorders (SSD) are a group of diseases characterized by one or more abnormal features in perception, thought processing and behavior. Patients suffering from SSD are at risk of developing life-threatening complications. Pharmacogenetic studies have shown promising results on personalized treatment of psychosis. In the current study, 103 patients diagnosed with SSD treated with risperidone as antipsychotic monotherapy were enrolled. Socio-demographics and clinical data were recorded, and laboratory tests and genotyping standard procedure for cytochrome P450 (CYP) 2D6*4 were performed. Patients were evaluated by the Positive and Negative Syndrome Scale (PANSS) on admission and at discharge. Based on the reduction in the PANSS total score, subjects were divided into non-responders, partial responders and full responders. Only 11 subjects had a full response to risperidone (10.67%), 53 subjects (51.45%) had a partial response, and 39 participants (37.86%) were non-responders. Patients at first episode psychosis showed significantly higher levels of blood glucose and prolactin levels, while chronic patients showed significantly higher LDL levels. Adverse drug reactions (ADR) such as tremor and stiffness significantly correlated with genetic phenotypes (p = 0.0145). While CYP2D6 showed no impact on treatment response, ADR were significantly more frequent among poor and intermediate metabolizers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosciences-Psychiatry, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
- Timis County Emergency Clinical Hospital "Pius Brinzeu", Liviu Rebreanu 156, 300723 Timisoara, Romania.
- Doctoral School, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
- Discipline of Medical Genetics, Department of Microscopic Morphology, Center of Genomic Medicine "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square 2, 300041 Timisoara, Romania.
- Independent Researcher, 300523 Timiosara, Romania.
ORCID-Profile: Mariana Bondrescu, Nicoleta Andreescu
Förderung
- “Victor Babes” University of Medicine and Pharmacy Timisoara
Zitieren
APA
Bondrescu, M., Dehelean, L., Farcas, S., Dragan, P. A., Podaru, C. A., Popa, L., & Andreescu, N. (2024). Into a Deeper Understanding of CYP2D6’s Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126350
Vancouver
Bondrescu M, Dehelean L, Farcas S, Dragan PA, Podaru CA, Popa L, et al. Into a Deeper Understanding of CYP2D6’s Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126350
BibTeX
@article{Bondrescu2024,
author = {Bondrescu, Mariana and Dehelean, Liana and Farcas, Simona and Dragan, Patricia Alexandra and Podaru, Carla Andreea and Popa, Laura and Andreescu, Nicoleta},
title = {Into a Deeper Understanding of CYP2D6’s Role in Risperidone Monotherapy and the Potential Side Effects in Schizophrenia Spectrum Disorders},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126350}
}
EUVIMED